CNBC Fast Money
2026-09-21 · Hosted by Melissa Lee · CNBC
Executive Summary
Semiconductor stocks rose more than 2% Friday, led by Teradyne, KLA Tencor, and Monolithic Power, but the group remains down double digits for the quarter versus a 15% gain for the software-focused IGV ETF. Traders on the desk were split on direction, but Tim Seymour argued semis are "breaking higher" given no letting-up in AI CapEx — Wall Street projects $1.3 trillion in hyperscaler capital spending next year. Steve Grasso favored the SMH ETF over the SOX index given its heavier Nvidia and Micron weighting, positioning those names as the largest beneficiaries of rising capex.
Key Stories & Changes
1. Semiconductor Stocks Show Signs of Inflection After Underperforming Software
Semis up >2% Friday; SOX index down double digits this quarter vs. +15% for software's IGV
Tim Seymour: no letup expected in AI CapEx heading into the Trump-Xi summit; $1.3 trillion in hyperscaler capex projected for next year
Steve Grasso prefers SMH (22% Nvidia weight, 5% Micron) over SOX (9%/9%) given capex flows benefiting Nvidia and Micron disproportionately
Nebius (neocloud) raised compute rental prices roughly 20% this week, seen as evidence of durable pricing power for legacy chip capacity
2. Healthcare Leads S&P Sectors; Rate-Biotech Correlation Debunked
Healthcare up almost 2% since Monday; Moderna, Dexcom, Thermo Fisher among top gainers
Mizuho's Jared Holt: 20-year data shows no meaningful correlation between rates and biotech performance once the pandemic-era zero-rate anomaly is excluded
3. Novo Nordisk Investor Day Looms as Stock Lags Peers
NVO: Novo Nordisk — -15% YTD — Investor day Monday; street wants business-development clarity beyond Wegovy
LLY: Eli Lilly — +7% YTD — Widely seen as having "won" the obesity race
MRK: Merck — +40% YTD — Re-rated on aggressive BD deals, moved past Keytruda patent-cliff fears
Jared Holt: Novo likely to look for acquisitions outside metabolic/obesity given competitive gap to Lilly
GLP-1 drug prices have fallen from roughly $1,200/month to $300-400/month, pressuring the "consumer product" framing even as volumes remain strong
4. Apple iPhone 18 Pro Launch: Strong Demand, Stretched Valuation
iPhone 18 Pro/Pro Max on sale Friday, the first major product launch under CEO John Ternus
Apple up 24% YTD, best-performing Mag 7 name, trading around 35x forward earnings
Julie Biel: "uncomfortably expensive" at current price despite genuine interest in the device lineup
Tim Seymour: valuation "hasn't mattered" given defensive balance sheet and growth reacceleration; 75% services margins support the bull case
Margin risk flagged from rising memory prices ahead of Q4 earnings
5. Trump-Xi Summit Preview: AI, Trade, Rare Earths on Agenda
Confirmed attendees at Thursday's state dinner include Nvidia's Jensen Huang, OpenAI's Sam Altman, JPMorgan's Jamie Dimon, and Citigroup's Jane Fraser
Treasury Secretary Scott Bessent leads pre-summit working-level talks this weekend on AI, trade, and rare earths
Expectations for major deliverables are "pretty muted"; possible trade-truce extension or AI safety dialogue establishment
Tim Seymour: bullish on agricultural exposure given China's record trade surplus heading into talks
6. Anthropic Reportedly Delays IPO to November
Wall Street Journal reports Anthropic pushed its planned IPO from October to November amid industry pacing concerns
Kalshi probability of an announcement by November 1 fell to 6%
Julie Biel flagged unit economics and training-cost disclosures in the eventual S-1 as the most closely watched detail
7. Nike Loses Mbappé to On Holding; Disney Hires First CTO
Kylian Mbappé left Nike for Swiss rival On Holding; Nike shares hit 12-year lows and face potential removal from the Dow
Disney created a new Chief Technology Officer role, hiring Character AI CEO Karandeep Anand (ex-Meta, Microsoft) to report directly to CEO Josh D'Amaro
Move follows the collapse of Disney's earlier Sora/OpenAI content-licensing partnership
Trends Identified
1. Semis-vs-Software Rotation Reaches an Inflection
The desk's split on whether semis are "breaking higher" or "breaking down" reflects a broader market debate also visible on Bloomberg Tech and CNBC Closing Bell the same day: whether 1H 2026's software outperformance was a temporary overcorrection or a durable structural shift away from picks-and-shovels AI plays.
2. GLP-1 Trade Has Bifurcated Beyond Novo/Lilly
The panel's observation that Merck — not a pure-play obesity name — is the year's best pharma performer suggests investors have rotated away from framing GLP-1 exposure as a two-horse race, rewarding business-development agility instead.
3. Mega-Cap Valuation Discomfort Persists Despite Bullish Consensus
Even traders constructive on Apple's long-term "owns the customer" thesis flagged 35x forward earnings as stretched, echoing a recurring theme across today's shows: strong fundamentals coexisting with valuation anxiety at the index's largest constituents.
4. AI Pacing Concerns Are Bleeding Into Capital Markets Timing
Anthropic's IPO delay, alongside SoftBank's leveraged OpenAI financing reported elsewhere today, shows the AI-safety debate is starting to directly affect deal and listing timelines, not just sentiment. ---
Sentiment Analysis
Overall Market Sentiment: Cautiously Constructive
Traders leaned bullish on AI infrastructure demand and healthcare but flagged valuation concerns on both Apple and the broader "expensive market" framing that closed the show.
Risk Factors Highlighted
AI CapEx pause risk: A slowdown in frontier-lab pacing could ripple through semis and hyperscaler capex commitments.
Apple margin compression: Rising memory prices ahead of Q4 earnings could pressure the new iPhone lineup's margins.
GLP-1 pricing degradation: Continued price erosion ($1,200 to $300-400/month) threatens the consumer-health investment thesis.
Summit disappointment: Muted expectations for the Trump-Xi meeting could disappoint markets pricing in AI/trade breakthroughs.
Anthropic IPO/unit economics uncertainty: Delayed listing raises questions about training-cost disclosure and profitability timeline.
Nike brand erosion: Loss of marquee athlete endorsements and potential Dow removal signal deeper competitive erosion.
Iran/oil volatility: Persistent geopolitical risk flagged as a wildcard for energy-sensitive trades.
This episode was covered in today's [The Market Signal — 2026-09-21](https://marketsignal.beehiiv.com/p/the-market-signal-2026-09-21), a cross-source synthesis of multiple podcast reports.